Provided by Tiger Trade Technology Pte. Ltd.

SIHUAN PHARM

0.720
-0.020-2.70%
Volume:14.25M
Turnover:10.23M
Market Cap:6.56B
PE:31.27
High:0.730
Open:0.730
Low:0.710
Close:0.740
52wk High:1.896
52wk Low:0.710
Shares:9.12B
HK Float Shares:9.12B
Volume Ratio:0.87
T/O Rate:0.16%
Dividend:0.02
Dividend Rate:3.03%
EPS(LYR):0.023
ROE:5.57%
ROA:2.73%
PB:0.91
PE(LYR):31.27
PS:2.13

Loading ...

BRIEF-Sihuan Pharma Signs Strategic Collaboration With Biocytogen For AI-Driven Drug R&D

Reuters
·
Apr 01

SIHUAN PHARM and BIOCYTOGEN-B Forge Strategic Alliance to Accelerate Innovative Drug Development in Weight Loss and Other Areas Using AI-Powered Human Antibody Platform

Stock News
·
Apr 01

Sihuan Pharm partners with Biocytogen to accelerate AI-driven fully human antibody R&D for next-gen weight-loss therapy

Bulletin Express
·
Apr 01

Sihuan Pharma signs strategic R&D collaboration with Biocytogen on AI antibody platform

Reuters
·
Apr 01

Sihuan Pharma - First Project Focuses on Next-Generation Weight Loss Drug

THOMSON REUTERS
·
Apr 01

Sihuan Pharma: March 2026 Share Capital Stable, No New Issuances or Treasury Movements

Bulletin Express
·
Apr 01

Sihuan Pharmaceutical Declares RMB 0.0096 Final Dividend for FY 2025

Bulletin Express
·
Mar 31

Sihuan Pharmaceutical Returns to Profitability with FY Net Income of 180 Million Yuan

Stock News
·
Mar 31

Sihuan Pharmaceutical 2025 Results: Revenue Climbs 37.7%, Turns Profitable on Medical Aesthetics Surge

Bulletin Express
·
Mar 31

Sihuan Pharma FY25 revenue climbs 37.7% to RMB 2.6 billion

Reuters
·
Mar 31

Sihuan Pharma - FY Profit Attributable RMB179.7 Mln

THOMSON REUTERS
·
Mar 31

Sihuan Pharma - Final Cash Dividend of RMB0.96 Cents per Share

THOMSON REUTERS
·
Mar 31

Xuanzhu Biopharma FY25 loss narrows 55.9% to RMB 250 million

Reuters
·
Mar 30

Sihuan Pharmaceutical unit publishes BRIGHT-2 Phase 3 results for biloxcilib plus fulvestrant in JAMA Oncology

Reuters
·
Mar 24

Xuanzhu Biopharmaceutical reports BRIGHT-2 Phase 3 results for Bireociclib plus fulvestrant in HR+/HER2- breast cancer

Reuters
·
Mar 24

Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis

Reuters
·
Mar 22

Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets

Reuters
·
Mar 22

Sihuan Pharma (00460) Schedules 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express
·
Mar 19